U.S. License Holder:
Xbrane
Date of License:
aBLA accepted by FDA June-2023; Complete Response Letter April-2024
Last Update:
Dec-15-2024
FDA-Approved Indications
Xlucane (ranibizumab) is not FDA-approved. An aBLA has been accepted by the FDA.